Phase I/IIa trial of the mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) administered orally in patients with refractory or advanced malignancies and sarcoma Academic Article uri icon

Overview

MeSH Major

  • Neoplasms
  • Sarcoma
  • Sirolimus
  • TOR Serine-Threonine Kinases

abstract

  • Oral ridaforolimus had an acceptable safety profile and exhibited antitumor activity in patients with sarcoma and other malignancies. ClinicalTrials.gov Identifier NCT00112372.

publication date

  • April 2013

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1093/annonc/mds602

PubMed ID

  • 23211938

Additional Document Info

start page

  • 1104

end page

  • 11

volume

  • 24

number

  • 4